Open Access

SGLT2 inhibitors in practice (part 3): the case for early intervention in HFrEF

Event: ESC Congress 2022
Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)
Session type: Satellite Symposium
Sponsored by Boehringer Ingelheim & Eli Lilly
Date: 27 August 2022
Time: 15:30 - 16:15

Congress Session

This content is currently on OPEN ACCESS

Sign in to view the resources

3 presentations in this session

Introduction, recap and overview of evidence for SGLT2 inhibitors in HFrEF.

Speaker: Professor J. Butler (Jackson, US)
Thumbnail

Implementing an SGLT2i for HFrEF treatment in my practice.

Speaker: Professor A. Coats (Coventry, GB)
Thumbnail

Panel discussion.

Speaker: Professor S. Anker (Berlin, DE)
Thumbnail

3 speakers from this session

Professor Javed Butler

The University of Mississippi Medical Center, Jackson (United States of America)
71 presentations
5 followers

Professor Andrew Coats

University of Warwick, Coventry (United Kingdom of Great Britain & Northern Ireland)
96 presentations
14 followers

Professor Stefan Anker

Charite Universitatsmedizin Berlin, Berlin (Germany)
116 presentations
4 followers

This platform is supported by

logo Novo Nordisk